229 related articles for article (PubMed ID: 34342126)
41. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
42. Controlled drug delivery with nanoassemblies of redox-responsive prodrug and polyprodrug amphiphiles.
Deng Z; Liu S
J Control Release; 2020 Oct; 326():276-296. PubMed ID: 32682899
[TBL] [Abstract][Full Text] [Related]
43. Modular Engineering of Targeted Dual-Drug Nanoassemblies for Cancer Chemoimmunotherapy.
Kang T; Li Y; Wang Y; Zhu J; Yang L; Huang Y; Xiong M; Liu J; Wang S; Huang M; Wei X; Gou M
ACS Appl Mater Interfaces; 2019 Oct; 11(40):36371-36382. PubMed ID: 31490057
[TBL] [Abstract][Full Text] [Related]
44. In vivo tailor-made protein corona of a prodrug-based nanoassembly fabricated by redox dual-sensitive paclitaxel prodrug for the superselective treatment of breast cancer.
Zhang D; Yang J; Guan J; Yang B; Zhang S; Sun M; Yang R; Zhang T; Zhang R; Kan Q; Zhang H; He Z; Shang L; Sun J
Biomater Sci; 2018 Aug; 6(9):2360-2374. PubMed ID: 30019051
[TBL] [Abstract][Full Text] [Related]
45. Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy.
Sun B; Luo C; Cui W; Sun J; He Z
J Control Release; 2017 Oct; 264():145-159. PubMed ID: 28844757
[TBL] [Abstract][Full Text] [Related]
46. Block copolymer prodrugs: Synthesis, self-assembly, and applications for cancer therapy.
Dutta D; Ke W; Xi L; Yin W; Zhou M; Ge Z
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1585. PubMed ID: 31452353
[TBL] [Abstract][Full Text] [Related]
47. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Jin Y; Yang F; Du L
Colloids Surf B Biointerfaces; 2013 Dec; 112():421-8. PubMed ID: 24036626
[TBL] [Abstract][Full Text] [Related]
48. Carrier-Free Nanomedicine for Cancer Immunotherapy.
Fu Y; Bian X; Li P; Huang Y; Li C
J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
[TBL] [Abstract][Full Text] [Related]
49. Microfluidic assembly of small-molecule prodrug cocktail nanoparticles with high reproducibility for synergistic combination of cancer therapy.
Li T; Huang J; Wang M; Wang H
Int J Pharm; 2021 Oct; 608():121088. PubMed ID: 34530101
[TBL] [Abstract][Full Text] [Related]
50. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release.
Li Y; Niu Y; Zhu J; Gao C; Xu Q; He Z; Chen D; Xu M; Liu Y
Nanoscale; 2020 Jan; 12(4):2673-2685. PubMed ID: 31942900
[TBL] [Abstract][Full Text] [Related]
51. Stimulus-responsive self-assembled prodrugs in cancer therapy.
Dong X; Brahma RK; Fang C; Yao SQ
Chem Sci; 2022 Apr; 13(15):4239-4269. PubMed ID: 35509461
[TBL] [Abstract][Full Text] [Related]
52. Nanoparticles as delivery carriers for anticancer prodrugs.
Fang JY; Al-Suwayeh SA
Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
[TBL] [Abstract][Full Text] [Related]
53. The application of prodrug-based nano-drug delivery strategy in cancer combination therapy.
Ge Y; Ma Y; Li L
Colloids Surf B Biointerfaces; 2016 Oct; 146():482-9. PubMed ID: 27400243
[TBL] [Abstract][Full Text] [Related]
54. Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy.
Liu J; Zhao D; He W; Zhang H; Li Z; Luan Y
J Colloid Interface Sci; 2017 Feb; 487():239-249. PubMed ID: 27776282
[TBL] [Abstract][Full Text] [Related]
55. The novel platinum(IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer.
Yang C; Tu K; Gao H; Zhang L; Sun Y; Yang T; Kong L; Ouyang D; Zhang Z
Biomaterials; 2020 Feb; 232():119751. PubMed ID: 31918218
[TBL] [Abstract][Full Text] [Related]
56. Recent trends in bioresponsive linker technologies of Prodrug-Based Self-Assembling nanomaterials.
Nguyen A; Böttger R; Li SD
Biomaterials; 2021 Aug; 275():120955. PubMed ID: 34130143
[TBL] [Abstract][Full Text] [Related]
57. Exquisite Vesicular Nanomedicine by Paclitaxel Mediated Co-assembly with Camptothecin Prodrug.
Zhou Z; Du C; Zhang Q; Yu G; Zhang F; Chen X
Angew Chem Int Ed Engl; 2021 Sep; 60(38):21033-21039. PubMed ID: 34278702
[TBL] [Abstract][Full Text] [Related]
58. Stimuli-responsive nanoassemblies for targeted delivery against tumor and its microenvironment.
Sia CS; Lim HP; Tey BT; Goh BH; Low LE
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188779. PubMed ID: 35977690
[TBL] [Abstract][Full Text] [Related]
59. Minor Changes in Response Modules Leading to a "U-Shaped" Conversion Rate of Docetaxel Prodrug Nanoassemblies.
Li W; Wang D; Zhao H; Xu H; Li L; Huang Y; Shi X; Sun J; He Z; Sun B
Nano Lett; 2024 Jan; 24(1):394-401. PubMed ID: 38147432
[TBL] [Abstract][Full Text] [Related]
60. Dynamic core crosslinked camptothecin prodrug micelles with reduction sensitivity and boronic acid-mediated enhanced endocytosis: An intelligent tumor-targeted delivery nanoplatform.
Huang Y; Zhang W; Xu Y; Zhu S; Wu Y; Chen T; Xiao Y; Lu W; Zhang X; Yu J
Int J Pharm; 2020 Apr; 580():119250. PubMed ID: 32209369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
